Breast cancer detection in its early stages significantly improves survival rates, according to medical experts. While ...

Having counseled thousands of patients through their breast cancer diagnosis, I was fully aware of how nondiscriminatory this ...

Dr. Balazs Halmos discusses the significance of the FDA approval of the subcutaneous injection formulation of Opdivo for ...

Patients with HR+/HER2− metastatic breast cancer without previous systemic therapy were randomly assigned to receive either metronomic capecitabine plus AI or AI alone.

Sanofi's phase 3 study shows Sarclisa SC matches IV formulation in efficacy for relapsed myeloma. Regulatory submissions are planned for 2025.

Sanofi's Blood Cancer Drug's New Subcutaneous Formulation Hits Primary Goal In Late-Stage In Multiple Myeloma Vandana Singh Thu, Jan 9, 2025, 10:57 AM 2 min read ...

Sanofi SNY announced that the phase III IRAKLIA study, which evaluated a fixed-dose subcutaneous (SC) formulation of its blood cancer drug, Sarclisa (isatuximab) for the treatment of relapsed or ...

because the scar tissue can obscure the breast cancer cells. In the new Visica Treatment System, cold therapy or 'cryoablation' attacks the unwanted lumps in a technique similar to that used to ...

Sanofi SNY announced that the phase III IRAKLIA study, which evaluated a fixed-dose subcutaneous (SC) formulation of its ...

“Our company can typically cover breast and prostate cancer survivors if they are three years post-treatment, although the cost can be significantly higher,” explains Pugh of Legal & General.